Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback